Artur Gabor - HELIX BIOPHARMA Director
| HBP Stock | EUR 0.23 0.00 0.00% |
Director
Mr. Artur Gabor is Director of the Company. Mr. Gabor has extensive experience in merger and acquisitions, corporate finance and restructuring. since 2019.
| Tenure | 5 years |
HELIX BIOPHARMA Leadership Team
Elected by the shareholders, the HELIX BIOPHARMA's board of directors comprises two types of representatives: HELIX BIOPHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HELIX. The board's role is to monitor HELIX BIOPHARMA's management team and ensure that shareholders' interests are well served. HELIX BIOPHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HELIX BIOPHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Albert Beraldo, Director | ||
| Artur Gabor, Director | ||
| Steve Demas, COO | ||
| Marek Orlowski, Independent Director | ||
| Slawomir Majewski, Independent Director | ||
| George Anders, Director | ||
| Heman Chao, Chief Scientific Officer | ||
| Theordore Witek, Director | ||
| Zbigniew Markowski, CEO | ||
| Sylwester Cacek, Director | ||
| Sven Rohmann, Independent Director | ||
| Photios Michalargias, CFO | ||
| Patrick Frankham, COO |
HELIX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HELIX BIOPHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 29.03 M | |||
| Price To Book | 50.71 X | |||
| EBITDA | (6.53 M) | |||
| Net Income | (6.56 M) | |||
| Cash Flow From Operations | (6.51 M) | |||
| Number Of Employees | 13 | |||
| Market Capitalization | 38.94 M | |||
| Total Asset | 3.73 M | |||
| Z Score | -3.3 | |||
| Net Asset | 3.73 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HELIX BIOPHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for HELIX Stock analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |